

Clarification of May 1, 2023 AMA Coronavirus (SARS-CoV-2) Posting

It is important to note that the CPT codebook states to select the name of the procedure or service that adequately identifies the service performed.

The intent of the new AMA Coronavirus (SARS-CoV-2) documents, released to the AMA website on May 1, 2023, was to communicate the recent FDA decision to remove Emergency Use Authorization (EUA) for the monovalent vaccines represented by the following CPT codes for vaccine product and their administration: 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A 91300, 91301, 91305, 91306, 91307, 91308, 91309 and 91311. The document also included the date of April 18, 2023 as the date of EUA removal.

Deletion of a CPT code is a decision made by the CPT Editorial Panel; those actions are independent of EUA decisions. At this time, the CPT vaccine product and administration codes remain in the CPT code set in order to facilitate any final reporting needs for the healthcare community for dates of service prior to April 18, 2023. Any further action regarding these monovalent product and administration codes is pending further review by the CPT Editorial Panel.

Questions regarding appropriate dosing of patients who may have received a monovalent vaccine during their course of therapy should be referred to the FDA and/or CDC for the most recent guidelines.

Additional information regarding these CPT codes can also be found in the [May 2023 special edition of the CPT Assistant guide](#).